A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

PHASE4CompletedINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

October 18, 2018

Primary Completion Date

April 12, 2019

Study Completion Date

April 12, 2019

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Dulaglutide Pen

Injected on a practice pad.

DRUG

Semaglutide Pen

Injected on a practice pad.

Trial Locations (14)

17011

BRCR Medical Center, Inc., Camp Hill

20110

Manassas Clinical Research Center, Manassas

20814

Evidera, Bethesda

22003

PI-Coor Clinical Research, LLC, Annandale

28150

Carolina Research Center, Inc., Shelby

30078

Georgia Clinical Research, Snellville

34684

Palm Harbor Medical Associates, Palm Harbor

40213

L-Marc Research Center, Louisville

58104

Lillestol Research LLC, Fargo

60607

Cedar-Crosse Research Center, Chicago

77040

Juno Research, Houston

77054

Juno Research, LLC, Houston

90807

Long Beach Center for Clinical Research, Long Beach

93720

Valley Research, Fresno

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03724981 - A Study Comparing the Dulaglutide Pen and the Semaglutide Pen | Biotech Hunter | Biotech Hunter